News

A prospective multicenter study in the Aesthetic Surgery Journal followed patients treated with a next-generation poly-L-lactic acid biostimulator in the nasolabial folds for a year, reporting effectiveness, satisfaction and safety. Biostimulators are a different treatment from hyaluronic acid rather than a longer-lasting version of it: they deposit a material the body answers by making collagen, so the result builds over months and fades over years. Durability data therefore matters more here than it does for a gel that dissolves.

Aesthetic surgery journal, “Effectiveness, Patient Satisfaction, and Safety of a Next-generation PLLA Collagen Biostimulator for Nasolabial Fold Augmentation: 12-month Results of a Prospective Multicenter Study.” — read the original

Read the full guide: Which Filler Goes Where — and Why the Brand Matters Less Than the Plane →

Dermatologic Surgery examined whether patients using a retinoid around the time of ablative laser resurfacing developed less post-inflammatory hyperpigmentation, in the skin types where that risk is highest. Pigment left behind after resurfacing is the complication that decides candidacy in darker skin, and it is why a treatment that suits one patient is a poor idea for another with the same finding. Anything that shifts that risk changes the conversation about who is a candidate, not the settings on the machine.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], “Post-inflammatory Hyperpigmentation After Ablative Laser Resurfacing in Darker Skin: Are Concurrent Retinoids Protective?” — read the original

Read the full guide: Fractional CO2 Recovery, Day by Day: What the Two Weeks Actually Look Like →

A randomized, double-blind trial in the Aesthetic Surgery Journal mapped injection points and escalating doses for botulinum toxin in the lower face. The lower face is where the muscles are doing more work than most people realize, and where a few units in the wrong place changes a smile rather than a line. Mapped dosing studies are how that becomes a technique rather than an individual injector's preference.

Aesthetic surgery journal, “Injection Mapping and Dose Escalation For Botulinum Toxin Treatment on the Lower Face: A Randomized, Double-blind Clinical Trial.” — read the original

Read the full guide: Botox Timing: Starting, Spacing, and What “Preventative” Really Buys You →

NewBeauty put the interleukin numbers that turn up in treatment advertising to a panel of dermatologists. It is a useful piece because the numbers are real immunology being used as marketing texture: they matter enormously for prescription biologics in eczema and psoriasis, and they mean close to nothing printed on a cosmetic serum. A figure with no unit and no reference is branding wearing a lab coat.

NewBeauty, “What Those Confusing IL Numbers in Skin-Treatment Ads Actually Mean” — read the original

Read the full guide: How to Read an Aesthetics Ad →

NewBeauty reports that Kylie Jenner documented a microneedling appointment on social media, numbing cream included. The coverage is worth using for the treatment rather than the person: microneedling has reasonable controlled evidence for acne scarring and skin texture over a series of three to six sessions, and very little for tightening. The depth the needles are set to is the whole treatment, which is why a professional device and a home roller with the same name are different procedures.

NewBeauty, “Kylie Jenner Gave Her Microneedling Appointment the Selfie Treatment” — read the original

See how it's graded: Microneedling →

Facial Plastic Surgery and Aesthetic Medicine takes on how the comparison between SMAS and deep plane techniques is now being conducted on social platforms instead of in the literature. The term has become a marketing tier, applied to operations that are nothing of the kind, and the paper is worth reading for how quickly a technical distinction turns into a claim. The anatomy has not changed; the volume around it has.

Facial plastic surgery & aesthetic medicine, “The Superficial Musculoaponeurotic System Versus Deep Plane Facelift Debate in the Instagram and TikTok Era.” — read the original

Read the full guide: Deep Plane or SMAS: What Actually Differs, and Who Each One Suits →

NewBeauty reports that the operation has shifted away from taking tissue out and toward repositioning what has moved. That matches what I see: the sunken, hollowed look people picture when they imagine eyelid surgery is largely the older technique, where lower-lid fat was excised rather than moved down into the hollow beneath it. The change matters most for the lower lid, where removing fat from a face that is already deflating ages it.

NewBeauty, “What ‘Modern Blepharoplasty’ Really Means Now” — read the original

Read the full guide: Heavy Eyes: What Is Skin, What Is Fat, and What Is Actually the Brow →

Allure examines Volufiline, a plant-derived ingredient blend marketed as adding volume to hollow areas from a bottle, and asks the experts whether it delivers. The claim runs into the same wall every topical volume claim does: the molecules are large, the barrier is designed to exclude them, and volume lives several millimeters below where a cream can reach. Some ingredients in this class do produce a mild local swelling that reads as fullness for a while, which is a real effect and a different one from what is being sold.

Allure — Skin, “Volufiline Users Say It’s “Filler in a Bottle”—But Is It?” — read the original

Read the full guide: What a Topical Can Actually Reach →

Elle reports on Re2O, an injectable derived from human cadaver tissue that has spread through Seoul's clinics on the back of the polynucleotide trend, and links its rise to GLP-1 weight loss. The connection is real: rapid weight loss empties facial fat compartments, and a large market has appeared for anything promising to put volume back without surgery. What these products do not have is the volume. They are skin-quality treatments being pulled toward a structural problem, and the regulatory position on tissue-derived injectables is not what most people assume.

Elle — Beauty, “How Ozempic Is Fueling the Rise of Cadaver-Derived Injectables” — read the original

Read the full guide: GLP-1 Weight Loss and the Face: What Empties, and What Puts It Back →

A review in the Aesthetic Surgery Journal examined forty-six U.S. civil cases involving injectable fillers between 1967 and 2025. Verdicts split almost evenly overall, and autologous fat, hyaluronic acid and biostimulators were implicated in roughly equal numbers. Two findings stand out: cases arising from med-spa procedures produced a plaintiff verdict every time, against forty-seven percent in private clinics and hospitals, and cases involving products without regulatory approval did the same. Neither the injector's credentials nor the severity of the complication predicted the outcome on its own.

Aesthetic surgery journal, “Litigating Filler Complications: Five Decades of Legal Outcomes in the United States.” — read the original

Read the full guide: Which Filler Goes Where — and Why the Brand Matters Less Than the Plane →

Lasers in Surgery and Medicine reports a sixty-two-year-old woman who suffered an embolic stroke after full-field ablative Erbium:YAG resurfacing. The proposed mechanism is specific and worth understanding: significant pain during the procedure prompted a Valsalva maneuver, and a previously unknown patent foramen ovale allowed a clot to cross from the venous side to the arterial one. This is a single case report of a first-described event, so it says nothing about the general risk of resurfacing. What it does argue for is adequate anesthesia during ablative treatment, because pain that makes someone bear down is a mechanism and not just discomfort.

Lasers in surgery and medicine, “Stroke Following Facial Laser Resurfacing Procedure-A Case Report.” — read the original

Read the full guide: Fractional CO2 Recovery, Day by Day: What the Two Weeks Actually Look Like →

Researchers in the Aesthetic Surgery Journal built an aged three-dimensional facial model, rejuvenated one region at a time, and asked a hundred and one observers to rank the results from youngest to oldest. The neck and jawline variant was ranked youngest most often; the perioral region was ranked oldest most often. It is a perception study on a digital model, not an outcomes study on patients, so it speaks to where attention goes rather than to what any operation achieves. It is still a useful argument for treating the face and neck as one unit.

Aesthetic surgery journal, “Impact of Facial Regions on Perceived Age: A 3-Dimensional Modeling Study.” — read the original

Read the full guide: Deep Plane or SMAS: What Actually Differs, and Who Each One Suits →

Writing in Elle, plastic surgeon Lara Devgan sets out the cosmetic treatments she declines for herself and steers patients away from. The genre is worth more than most aesthetic coverage, because a list of what somebody refuses is harder to fake than a list of what they recommend. It is also the question almost nobody asks in a consultation, and the one that separates a physician thinking about your face over a decade from one thinking about today.

Elle — Beauty, “I’m a Plastic Surgeon. These Are the Cosmetic Treatments I’d Never Do.” — read the original

Read the full guide: How to Read an Aesthetics Ad →